Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate

Stefano Ferrari, Franca Pieretti, Elisabetta Verri, Loredana Tolentinis, Marilena Cesari, Michela Versari, Carola Zolezzi, Gaetano Lamanna, Gaetano Bacci

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We investigated the renal function of pediatric and adult patients who had been submitted to chemotherapy with high-dose methotrexate (MTX), cisplatin and high-dose ifosfamide (IFO). We observed 43 osteosarcoma patients aged 4-34 years (median 16 years). The median received cumulative doses of MTX, cisplatin and IFO were 60.1 g/m2, 598 mg/m2 and 73.5 g/m2. Renal function was assessed by measurement of creatinine clearance, renal threshold for phosphate (Tmp/GFR), urinary α1-microglobulin (A1M):creatinine ratio, urinary albumin:creatinine ratio, 24-h glycosuria and proteinuria. The median interval between chemotherapy completion and first renal function assessment was 2 months (range 2-4 months); assessments were then performed at a median interval of 16 months (range 9-49 months). A significant decrease of TmP/GFR was observed only in the pediatric group (under 18 years): the percentage of patients with TmP/GFR <1 mmol/l increased from 21% (six of 28) at the end of treatment to 46% (13 of 28) at the late assessment. Glycosuria in 10 (67%) of 15 adults and 21 (75%) of pediatric patients was detected with an increased incidence compared to the early post-chemotherapy assessment (13% adults and 29% children). A significant increase of the albumin:creatinine ratio and A1M:creatinine ratio was observed only in adults. Overall, 21 patients had a reduced glomerular function at the latest evaluation, associated with glycosuria in 15 patients (71%), proteinuria in 14 (67%) and TmP/GFR <1 mmol/l in 11 (52%). We conclude that strict monitoring of renal function should be recommended in pediatric and adult patients after chemotherapy with high-dose MTX, cisplatin and high-dose IFO.

Original languageEnglish
Pages (from-to)733-738
Number of pages6
JournalAnti-Cancer Drugs
Volume16
Issue number7
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Ifosfamide
Methotrexate
Cisplatin
Pediatrics
Kidney
Creatinine
Glycosuria
Drug Therapy
Proteinuria
Albumins
Osteosarcoma
Phosphates
Incidence

Keywords

  • Cisplatin
  • High-dose ifosfamide
  • High-dose methotrexate
  • Nephrotoxicity
  • Osteosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate. / Ferrari, Stefano; Pieretti, Franca; Verri, Elisabetta; Tolentinis, Loredana; Cesari, Marilena; Versari, Michela; Zolezzi, Carola; Lamanna, Gaetano; Bacci, Gaetano.

In: Anti-Cancer Drugs, Vol. 16, No. 7, 08.2005, p. 733-738.

Research output: Contribution to journalArticle

Ferrari, Stefano ; Pieretti, Franca ; Verri, Elisabetta ; Tolentinis, Loredana ; Cesari, Marilena ; Versari, Michela ; Zolezzi, Carola ; Lamanna, Gaetano ; Bacci, Gaetano. / Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate. In: Anti-Cancer Drugs. 2005 ; Vol. 16, No. 7. pp. 733-738.
@article{e4a569a954d449a4b1f02c79dfda0535,
title = "Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate",
abstract = "We investigated the renal function of pediatric and adult patients who had been submitted to chemotherapy with high-dose methotrexate (MTX), cisplatin and high-dose ifosfamide (IFO). We observed 43 osteosarcoma patients aged 4-34 years (median 16 years). The median received cumulative doses of MTX, cisplatin and IFO were 60.1 g/m2, 598 mg/m2 and 73.5 g/m2. Renal function was assessed by measurement of creatinine clearance, renal threshold for phosphate (Tmp/GFR), urinary α1-microglobulin (A1M):creatinine ratio, urinary albumin:creatinine ratio, 24-h glycosuria and proteinuria. The median interval between chemotherapy completion and first renal function assessment was 2 months (range 2-4 months); assessments were then performed at a median interval of 16 months (range 9-49 months). A significant decrease of TmP/GFR was observed only in the pediatric group (under 18 years): the percentage of patients with TmP/GFR <1 mmol/l increased from 21{\%} (six of 28) at the end of treatment to 46{\%} (13 of 28) at the late assessment. Glycosuria in 10 (67{\%}) of 15 adults and 21 (75{\%}) of pediatric patients was detected with an increased incidence compared to the early post-chemotherapy assessment (13{\%} adults and 29{\%} children). A significant increase of the albumin:creatinine ratio and A1M:creatinine ratio was observed only in adults. Overall, 21 patients had a reduced glomerular function at the latest evaluation, associated with glycosuria in 15 patients (71{\%}), proteinuria in 14 (67{\%}) and TmP/GFR <1 mmol/l in 11 (52{\%}). We conclude that strict monitoring of renal function should be recommended in pediatric and adult patients after chemotherapy with high-dose MTX, cisplatin and high-dose IFO.",
keywords = "Cisplatin, High-dose ifosfamide, High-dose methotrexate, Nephrotoxicity, Osteosarcoma",
author = "Stefano Ferrari and Franca Pieretti and Elisabetta Verri and Loredana Tolentinis and Marilena Cesari and Michela Versari and Carola Zolezzi and Gaetano Lamanna and Gaetano Bacci",
year = "2005",
month = "8",
doi = "10.1097/01.cad.0000168394.89428.11",
language = "English",
volume = "16",
pages = "733--738",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate

AU - Ferrari, Stefano

AU - Pieretti, Franca

AU - Verri, Elisabetta

AU - Tolentinis, Loredana

AU - Cesari, Marilena

AU - Versari, Michela

AU - Zolezzi, Carola

AU - Lamanna, Gaetano

AU - Bacci, Gaetano

PY - 2005/8

Y1 - 2005/8

N2 - We investigated the renal function of pediatric and adult patients who had been submitted to chemotherapy with high-dose methotrexate (MTX), cisplatin and high-dose ifosfamide (IFO). We observed 43 osteosarcoma patients aged 4-34 years (median 16 years). The median received cumulative doses of MTX, cisplatin and IFO were 60.1 g/m2, 598 mg/m2 and 73.5 g/m2. Renal function was assessed by measurement of creatinine clearance, renal threshold for phosphate (Tmp/GFR), urinary α1-microglobulin (A1M):creatinine ratio, urinary albumin:creatinine ratio, 24-h glycosuria and proteinuria. The median interval between chemotherapy completion and first renal function assessment was 2 months (range 2-4 months); assessments were then performed at a median interval of 16 months (range 9-49 months). A significant decrease of TmP/GFR was observed only in the pediatric group (under 18 years): the percentage of patients with TmP/GFR <1 mmol/l increased from 21% (six of 28) at the end of treatment to 46% (13 of 28) at the late assessment. Glycosuria in 10 (67%) of 15 adults and 21 (75%) of pediatric patients was detected with an increased incidence compared to the early post-chemotherapy assessment (13% adults and 29% children). A significant increase of the albumin:creatinine ratio and A1M:creatinine ratio was observed only in adults. Overall, 21 patients had a reduced glomerular function at the latest evaluation, associated with glycosuria in 15 patients (71%), proteinuria in 14 (67%) and TmP/GFR <1 mmol/l in 11 (52%). We conclude that strict monitoring of renal function should be recommended in pediatric and adult patients after chemotherapy with high-dose MTX, cisplatin and high-dose IFO.

AB - We investigated the renal function of pediatric and adult patients who had been submitted to chemotherapy with high-dose methotrexate (MTX), cisplatin and high-dose ifosfamide (IFO). We observed 43 osteosarcoma patients aged 4-34 years (median 16 years). The median received cumulative doses of MTX, cisplatin and IFO were 60.1 g/m2, 598 mg/m2 and 73.5 g/m2. Renal function was assessed by measurement of creatinine clearance, renal threshold for phosphate (Tmp/GFR), urinary α1-microglobulin (A1M):creatinine ratio, urinary albumin:creatinine ratio, 24-h glycosuria and proteinuria. The median interval between chemotherapy completion and first renal function assessment was 2 months (range 2-4 months); assessments were then performed at a median interval of 16 months (range 9-49 months). A significant decrease of TmP/GFR was observed only in the pediatric group (under 18 years): the percentage of patients with TmP/GFR <1 mmol/l increased from 21% (six of 28) at the end of treatment to 46% (13 of 28) at the late assessment. Glycosuria in 10 (67%) of 15 adults and 21 (75%) of pediatric patients was detected with an increased incidence compared to the early post-chemotherapy assessment (13% adults and 29% children). A significant increase of the albumin:creatinine ratio and A1M:creatinine ratio was observed only in adults. Overall, 21 patients had a reduced glomerular function at the latest evaluation, associated with glycosuria in 15 patients (71%), proteinuria in 14 (67%) and TmP/GFR <1 mmol/l in 11 (52%). We conclude that strict monitoring of renal function should be recommended in pediatric and adult patients after chemotherapy with high-dose MTX, cisplatin and high-dose IFO.

KW - Cisplatin

KW - High-dose ifosfamide

KW - High-dose methotrexate

KW - Nephrotoxicity

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=23344449942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23344449942&partnerID=8YFLogxK

U2 - 10.1097/01.cad.0000168394.89428.11

DO - 10.1097/01.cad.0000168394.89428.11

M3 - Article

C2 - 16027521

AN - SCOPUS:23344449942

VL - 16

SP - 733

EP - 738

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 7

ER -